



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

## Elenco Oral Communications

ID	N.pgm	Title	Presenting Author
<b>20/06/2024 11.10 - 12.10 HIV epidemiology and testing promotion</b>			
210	OC 1	Measuring HIV knowledge and attitudes in the healthcare setting: Italian results from an ECDC/EACS survey	Maria Mazzitelli, Padova
353	OC 2	Modena and Emilia Romagna HIV Surveillance: the application of ECDC HIV Modelling Tool	Marianna Menozzi, Modena
149	OC 3	HIV testing in Italian community and outreach sites: COBATEST network, 2020-2023	Paolo Meli, Chiuduno BG
83	OC 4	Estimating the potential health economic value of universal opt-out HIV testing in emergency departments in Italy: A modelling study	Antonella d'Arminio Monforte, Milano
<b>20/06/2024 11.10 - 12.10 Immune responses to vaccination and emerging infections</b>			
246	OC 5	Humoral and cellular immune response after one year from Mpox virus infection	Eleonora Cimini, Roma
223	OC 6	Anti-MPXV humoral and cellular immune response one year after mpox infection or MVA-BN vaccination	Giulia Matusali, Roma
109	OC 7	SARS-CoV-2 spike protein and plasma from COVID-19 patients induce extracellular traps by myeloid-derived suppressor cells	Germana Grassi, Roma
134	OC 8	Antiretroviral therapy restores naïve T cell frequencies and functionality in PLWH	Beatrice Dallan, Ferrara
<b>20/06/2024 12.15 - 13.15 Long Acting injectables: the Italian experience</b>			
205	OC 9	One-year of long-acting cabotegravir and rilpivirine in people with HIV and a long exposure to antiretroviral therapy: data from the SCohoLART study	Camilla Muccini, Milano
185	OC 10	Effectiveness of long-acting ART with cabotegravir/rilpivirine in the Icona Cohort	Roberta Gagliardini, Roma
388	OC 11	Cabotegravir-rilpivirine long-acting injectable regimen: an analysis of the causes of interruption and impact of genotypic drug resistance in a multicentric cohort	Giada Canavesi, Legnano MI
179	OC 12	Pittsburgh sleep quality index (PSQI) changes in virologically suppressed people living with HIV switching to long acting cabotegravir and rilpivirine	Angelo Dargenio, Bari
<b>20/06/2024 14.20 - 15.20 Real-world experiences with TAF-based regimens</b>			
166	OC 13	Efficacy of switching to bicitegravir/emtricitabine/tenofovir alafenamide in people living with HIV with pre-existing NRTI resistances: a real-life experience	Antonio Di Biagio, Genova
228	OC 14	Adherence of single tablet antiretroviral regimens in the clinical setting: forgiveness does matter	Viviana Maccario, Torino
141	OC 15	Changes in Body mass index and lipid profile in PWH switching to a regimen without TAF vs PWH continuing TAF. Data from a real-life setting	Nicola Squillace, Monza



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

## Elenco Oral Communications

ID	N.pgm	Title	Presenting Author
<b>20/06/2024 14.20 - 15.20 Virology and pharmacology across the spectrum of HIV treatment</b>			
192	OC 16	Do low-frequency drug-resistant HIV-1 variants have a role on first-line INSTI-containing regimens? A case-control study from the ICONA cohort	Maria Santoro, Roma
54	OC 17	Long Acting Cabotegravir and Rilpivirine plasma and intracellular pharmacokinetics in the Clinical Setting	Micol Ferrara, Torino
177	OC 18	Network analysis of proviral DNA mutations in People with 4-class-resistant HIV-1: Data from the PRESTIGIO Registry	Sara Diotallevi, Milano
368	OC 19	The in vitro genetic barrier to resistance of lenacapavir is not affected by viral subtype or heavy treatment exposure	Chiara Paletti, Siena
<b>20/06/2024 15.25 - 17.30 Covid-19 and post-Covid conditions in 2024: data from the EuCARE project</b>			
292	OC 20	Interplay between gut-barrier dysfunction, microbial translocation, microbioma and SARS-CoV-2 RNAemia in acutely ill unvaccinated COVID-19 individuals developing long-covid	Roberta Rovito, Milano
225	OC 21	Trajectories of the Post COVID-19 condition	Andrea Santoro, Milano
<b>20/06/2024 15.25 - 16.25 Modern challenges in sexual health</b>			
439	OC 22	Female sexual dysfunction: prevalence and risk factors in a cohort of women living with HIV	Martina Salvi, Brescia
34	OC 23	Knowledge, use and misuse of self-prescribed doxyPEP in a community-based PrEP service	Pietro Leone Giovanni Vinti, Milano
274	OC 24	Effectiveness of MenB vaccination against gonorrhoeae among PrEP users and PWH	Giovanni Massobrio, Genova
446	OC 25	HPV test in anal specimens: a preliminary evaluation on sampling quality	Alberto Rizzo, Milano
<b>20/06/2024 16.30 - 17.30 The complexities of HIV infection</b>			
184	OC 26	All-cause mortality in people diagnosed with HIV in Italy in 1995-2019: data from the ICONA cohort	Andrea Giacomelli, Milano
273	OC 27	Burden of advanced HIV disease (AHD) among antiretroviral therapy (ART)-experienced persons with HIV (PWH) in Italy over the past 20 years	Annalisa Mondì, Roma
284	OC 28	Kidney transplantation in people living with HIV: ten-year experience in Modena	Adriana Cervo, Modena
364	OC 29	HIV advanced naive: the forgotten test	Arianna Narducci, Foggia



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

## Elenco Oral Communications

ID	N.pgm	Title	Presenting Author
<b>20/06/2024 16.30 - 17.30 Immunological features in people living with HIV</b>			
147	OC 30	Scant effect of cART on mucosal immune cells during acute HIV infection	Camilla Tincati, Milano
430	OC 31	Viro-immunological reservoirs characterization in PBMCs and GALT in individuals on dual and triple-ART regimens	Sohaib Khan, Roma
43	OC 32	Oxidative stress in virologically suppressed people with HIV: Is dual antiretroviral therapy associated with a more favourable profile?	Francesca Lombardi, Roma
367	OC 33	Characterization of specific T-cell responses to a Three-Doses nonavalent HPV Vaccine Schedule in PLWH on ART	Eeva Tortellini, Roma
<b>21/06/2024 10.05 - 11.05 Tailored approaches to antiretroviral therapy</b>			
269	OC 34	Clinical outcome of switching to a dual drug regimen (2DR) vs. switching or remaining on a triple (3DR) regimen in the setting of a viral load $\leq 50$ copies/mL	Alessandro Cozzi-Lepri, London UK
234	OC 35	Cumulative risk of discontinuation of modern first-line ART by reason for stopping and type of ART initiated: findings from the ICONA cohort	Mariacristina Polisenio, Bari
159	OC 36	CD4 T-cell, CD4/CD8 ratio improvement and a general reduction in inflammatory biomarkers with low level viremia (LLV) up to Week 192 with Fostemsavir (FTR) based regimens in individuals with multidrug-resistant (MDR) HIV-1	Vincenzo Spagnuolo, Milano
213	OC 37	Well-being in people with HIV after one year of long-acting cabotegravir and rilpivirine	Francesca Alberton, Milano
<b>21/06/2024 11.10 - 12.50 Critical clinical aspects underlining the control of viral hepatitis and emerging viral infections</b>			
240	OC 38	Persistent HBV cryptic activity is frequently revealed among anti-HBc positive/HBsAg negative people living with HIV infection during HBV-active ART and can jeopardize the full control of HIV replication	Lorenzo Piermatteo, Roma
324	OC 39	Chronic HDV coinfection (CHD) is characterized by a different HBsAg isoforms composition respect to HBV mono-infection with higher middle- and large-HBs levels paralleling the replicative and cytolytic activity of HDV	Alessia Magnapera, Roma
418	OC 40	Investigating seroprevalence of IgG against Dengue virus (DENV) in a cohort of people with HIV (PLWH) in a non-endemic country after an autochthonous outbreak: are we ready for next season?	Pierluigi Francesco Salvo, Roma
61	OC 41	Viral Respiratory Infections in Patients with Haematological Diseases over 10 Years: a single-center Experience	Patrizia Bono, Milano



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

## Elenco Oral Communications

ID	N.pgm	Title	Presenting Author
<b>21/06/2024 11.10 - 12.10 Awareness in Sexual Health: U=U and prevention</b>			
441	OC 42	Information and Misinformation on HIV and the Narration of the Evidence U=U: a mixed method analysis on social media in Italy	Virginia Casigliani, Pisa
277	OC 43	"U=U impossibile sbagliare" awareness campaign: impact assessment among PLWH	Antonella Cingolani, Roma
51	OC 44	Loss of "U=U status" in Women with HIV: insights into possible reasons for a higher risk compared to Men	Rosa Fontana Del Vecchio, Siracusa
111	OC 45	DoxyPEP is already used in two community-based centers in Bologna and Rome. An explorative survey	Marco Stizioli, Montichiari BS
<b>21/06/2024 14.00 - 15.00 A tale of two pandemics: molecular insights on SARS-CoV-2 and HIV</b>			
49	OC 46	Genomic epidemiology of the main SARS-CoV-2 variants circulating in Italy during the Omicron era	Annalisa Bergna, Milano
468	OC 47	Genomic characterization of SARS-CoV-2 Omicron variants and clinical presentation in immunocompromised and non-immunocompromised adult people	Maria Concetta Bellocchi, Roma
44	OC 48	Analysis of chromosome integration sites of HIV-1 DNA in PBMC of PWH showing plasma HIV-1 RNA detected only by the LTR target with Aptima HIV-1 Quant Dx assay	Giuseppe Sberna, Roma
128	OC 49	Post-translational HIV-1 integrase modification sites might be affected by complex and prolonged treatment history associated with multidrug resistance: a proof of concept study from the PRESTIGIO registry	Daniele Armenia, Roma
<b>21/06/2024 14.00 - 15.00 PrEP and prevention strategies</b>			
29	OC 50	Implementation of PrEP in Italy: results of PrIDE survey	Silvia Nozza, Milano
370	OC 51	HIV pre-exposure prophylaxis (PrEP) efficacy, adherence and persistence in an Italian multicentric cohort: ItaPrEP study	Valentina Mazzotta, Roma
342	OC 52	Overcoming HPV vaccination barriers in target populations: the VACCINAMILANO experience	Federico Barone, Milano
249	OC 53	HIV screening strategies in the Emergency department to reveal hidden infections	Andrea Santoro, Milano
<b>21/06/2024 14.00 - 15.00 HIV associated comorbidities: matters of the heart</b>			
335	OC 54	Incidence of metabolic syndrome in people with HIV in Italy who started ART since 2008: data from the ICONA cohort	Elena Bruzzesi, Milano
475	OC 55	Current and temporal exposure to integrase strand transfer inhibitors are not associated with hypertension or arterial stiffness in people with HIV	Matteo Mantovani, Modena
199	OC 56	Metabolic and weight changes in people with HIV after switching to long-acting therapy with cabotegravir and rilpivirine: results from the SCohoLART study	Martina Bottanelli, Milano
339	OC 57	Carotid intima media thickness (IMT) and statins prescriptions in the real life setting of the Archi Prevalent cohort	Benedetto Maurizio Celesia, Catania



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

## Elenco Oral Communications

ID	N.pgm	Title	Presenting Author
<b>21/06/2024 15.05 - 16.05 What is left to say on COVID-19 today?</b>			
254	OC 58	Inflammatory milieu and specific T cells response after three months and one year from SARS-CoV-2 infection	Eleonora Cimini, Roma
420	OC 59	Clinical features and impact on mortality of COVID-19 epidemics in patients with Non-Hodgkin lymphoma: long-term results from a tertiary center in Italy	Emanuela Zappulo, Napoli
376	OC 60	Time to anti-cancer treatment resumption after SARS-CoV-2 infection in patients with active hematological disease undergoing off-label combined antiviral treatments	Elena Matteini, Roma
66	OC 61	SARS-CoV-2 intra-host evolution during acute infection in COVID-19 patients	Alessia Lai, Milano
<b>21/06/2024 15.05 - 16.05 HIV associated comorbidities: pressing matters</b>			
371	OC 62	Cancers in people living with HIV: an observational study in the cohort of Modena over 27 years	Federica Prandini, Modena
280	OC 63	CNS relapse risk in HIV-positive patients affected by DLBCL and HGBL - a retrospective study of the MUSTHAL cohort	Luisa Verga, Monza
265	OC 64	Cognitive Performance in Older People with and without HIV in the GEPPPO Cohort	Andrea Calcagno, Torino
463	OC 65	Increasing prevalence of cognitive frailty in people living with HIV	Jovana Milic, Modena
<b>21/06/2024 15.05 - 16.05 Highlighting the diversity of people living with HIV</b>			
130	OC 66	Socio-demographic, clinical and therapeutic features of persons with HIV (PWH) currently in care in Italy: data from the ICONA cohort	Antonella d'Arminio Monforte, Milano
405	OC 67	Low prevalence of optimal health-related quality of life in real-world data among people with HIV	Eduardo Gnoatto Perondi, Modena
351	OC 68	African women living with HIV in Modena: far from fulfilling the gap	Federica Casari, Modena
461	OC 69	Pregnant women living with HIV: the experience of IRCCS San Gerardo dei Tintori	Fabiana D'Aloia, Monza